Search Back New search Go to resultsDiseaseMain groupHematologic NeoplasmsSolid TumorsProtocol groupDermatologic OncologyMyeloproliferative neoplasms (MPN) and myelodysplastic neoplasms (MDS)DiseaseMastocytosis, SystemicSubgroupICD10C94.3-C96.2MeSHMastocytosis, SystemicSequenceChemotherapyChemo-substanceAvapritinibCladribineHydroxyureaImatinibInterferon alpha-2a pegylatedMidostaurinChemo-substanceAvapritinibCladribineHydroxyureaImatinibInterferon alpha-2a pegylatedMidostaurinChemo-substanceAvapritinibCladribineHydroxyureaImatinibInterferon alpha-2a pegylatedMidostaurinChemo-substanceAvapritinibCladribineHydroxyureaImatinibInterferon alpha-2a pegylatedMidostaurinNo. Substances1 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronPegfilgrastimSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronPegfilgrastimSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronPegfilgrastimSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronPegfilgrastimNo. Substances234Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseTherapy intentiondisease controlpalliativeRisksAbdominal PainAlopeciaAnemia Hb below 8g/dlConstipationDepressionDiarrheaDrowsinessEdemaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaGastrointestinal ToxicityHeadacheIncrease Alkaline PhosphataseInfectionsLeukopeniaLymphopeniaNeutropeniaPruritusPyrexiaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorAlvarez-Twose IBarete SCasassus PGotlib JLim KHDiseaseaggr. syst. Mastozytose, Mastozytose mit hämatolog. Neoplasie, Mastzellenleukämie, ECOG 0-3Aggressive systemische Mastozytose, systemische Mastozytose mit assoziierter hämatologischer Neoplasie, Mastzellleukämie Systemische MastozytoseSystemische Mastozytose, KIT D816 negativSystemische Mastozytose, ohne Ansprechen auf die symptomatische Behandlung, oder zytoreduktive TherapieSystemische Mastozytose mit assoziierter hämatologischer NeoplasieOriginDivisions of Hematology, Mayo Clinic, Rochester, MinnesotaHematology Division, Stanford University School of Medicine–Stanford Cancer Institute, Stanford, CA Hopital Avicenne, Universite Paris-Nord, Bobigny, FranceSpanish Network on Mastocytosis (REMA), Toledo and Salamanca, SpainStanford Cancer Institute/Stanford University School of Medicine, Stanford, USA, PATHFINDER trialUPMC Univ Paris VI, Hopital Tenon, Paris, FranceProtocols in Revision 7 protocols foundProtocols under revision.Avapritinib 200, Systemic Mastocytosis (PID2071 V1.0)Cladribine 0.14, systemic mastocytosis (PID1680 V1.2)Cladribine 0.14, Systemic Mastocytosis, Variant 1 (PID2332 V1.1)Hydroxyurea 15, Systemic Mastocytosis (PID1804 V1.0)Imatinib 400, Systemic Mastocytosis (PID1806 V1.1)Midostaurin 100, Aggressive Systemic Mastocytosis (PID1082 V1.1)Peginterferon alpha-2a 90, Systemic Mastocytosis (PID1805 V1.0)
